Toxicity of upfront ¹³¹I-metaiodobenzylguanidine ( ¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: A retrospective analysis

Keyphrases

• Neuroblastoma 100%
• Retrospective Analysis 100%
• Newly Diagnosed 100%
• 131I-metaiodobenzylguanidine 100%
• Acute Toxicity 36%
• Vomiting 18%
• Nausea 18%
• Chemotherapy 9%
• Initial Treatment 9%
• Treatment Modalities 9%
• Second Dose 9%
• First Dose 9%
• Large Cohort 9%
• Anemia 9%
• High-risk Neuroblastoma 9%
• Autologous Stem Cell Rescue 9%
• Academic Medical Centers 9%
• Safe Treatment 9%
• Stage 4S 9%
• Thrombocytopenia 9%
• Children's Hospital 9%
• Leukocytopenia 9%
• Short-term Toxicity 9%
• Thrombocytopenia 2 9%
• Posterior Reversible Encephalopathy Syndrome 9%
• 1-stage 9%

Medicine and Dentistry

• Ganglioneuroblastoma 100%
• Iodine 131 100%
• (3 Iodobenzyl)guanidine 100%
• Acute Toxicity 36%
• Nausea and Vomiting 18%
• Thrombocytopenia 18%
• Disease 9%
• Stem Cell 9%
• Retrospective Study 9%
• Anemia 9%
• Leukopenia 9%
• Posterior Reversible Encephalopathy Syndrome 9%
• Chemotherapy 9%